Treatment of seasonal allergic rhinoconjunctivitis with a once-daily SQ-standardized grass allergy immunotherapy tablet

Current Medical Research and Opinion

Volumn 28, Issue 6, 2012, Pages 1043-1051

  Nelson, Harold ^a   Lehmann, Lucine ^b   Blaiss, Michael S ^c  

^a DEPARTMENT OF MEDICINE   (United States)

^b ALK ABELLÓ   (Denmark)

^c UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Adult; Allergic rhinoconjunctivitis; Children; Grass allergy immunotherapy tablet; Grass pollen; Specific immunotherapy

Indexed keywords

GRASS POLLEN VACCINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; LEVOCABASTINE; LORATADINE; PLACEBO; PREDNISONE;

ALLERGY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GRASS; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; OUTCOME ASSESSMENT; QUALITY OF LIFE; REVIEW; SEASONAL ALLERGIC CONJUNCTIVITIS; SINGLE DRUG DOSE; SYMPTOM; TABLET; TREATMENT DURATION;

ALLERGENS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CONJUNCTIVITIS, ALLERGIC; DESENSITIZATION, IMMUNOLOGIC; DRUG ADMINISTRATION SCHEDULE; HUMANS; MULTICENTER STUDIES AS TOPIC; PLANT EXTRACTS; POACEAE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REFERENCE STANDARDS; RHINITIS, ALLERGIC, SEASONAL; TABLETS;

EID: 84862545163     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.684676     Document Type: Review

References (43)

1. Bachau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64
2. Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc 2007;28:393-7
3. Bjorksten B, Clayton T, Ellwood P, et al. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol 2008;19:110-24
4. White P, Smith H, Baker N, et al. Symptom control in patients with hay fever in UK general practice: how well are we doing and is there a need for allergen immunotherapy? Clin Exp Allergy 1998;28:266-70
5. Frew AJ. Allergen immunotherapy. J Allergy Clin Immunol 2010;125:S306-13
6. Frew AJ, Powell RJ, Corrigan CJ, et al. Efficacy and safety of specific immu-notherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319-25
7. Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802-9
8. Bousquet J, Casale T, Lockey RF, et al. Sub-lingual immunotherapy. World Allergy Organisation position paper 2009. WAO Journal 2009;233-81. Available at: http://www.worldallergy.org/publications/slit-wao-pp/final.pdf
9. Di Bona D, Plaia A, Scafidi V, et al. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol 2010;126:558-66
10. Summary of Product Characteristics (SPC). Grazax 75,000 SQ-T oral lyophi-lisate. Available at: http://www.grazax.com/SiteCollectionDocuments/ Grazax.com/About20Grazax/Grazax/SmPC/MRP/VAR13/15OCT2010.pdf [Last accessed 28 March 2012]
11. Lombardi C, Incorvaia C, Braga M, et al. Administration regimens for sublin-gual immunotherapy to pollen allergens: what do we know? Allergy 2009;64:849-54
12. Hejl C, Wurtzen PA, Kleine-Tebbe J, et al. Phleum pratense alone is sufficient for allergen-specific immunotherapy against allergy to Pooideae grass pollens. Clin Exp Allergy 2009;39:752-9
13. Johansen N, Weber RW, Ipsen H, et al. Extensive cross-reactivity towards the Pooideae grasses substantiated for a large number of grass-pollen-sensitized subjects. Int Arch Allergy Immunol 2009; 150:325-34
14. Blaiss M, Maloney J, Nolte H, et al. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64-71
15. Bufe A, Eberle P, Franke-Beckmann E, et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167-73
16. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjuntivitis. Allergy 2006;61:185-90
17. Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immu-notherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434-40
18. Nelson HS, Nolte H, Creticos P, et al. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72-80
19. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma (ARIA) 2008. Allergy 2008;63(Suppl 86):8-160
20. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83
21. Juniper EF, Howland WC, Roberts NB, et al. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol 1998;101:163-70
22. Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP). Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. EMEA/CHMP/EWP/18504/2006. European Medicines Agency, 2008. Available at: www. ema.europa.eu [Last accessed 22 Nov 2011]
23. Durham S, Emminger W, Riis B, et al. Efficacy and safety of SQ-standardised grass allergy immunotherapy tablet in European and North American adults. Allergy 2011;66(Suppl 94):105-63
24. Bufe A, Tholstrup B, Maloney J, et al. Efficacy and safety of SQ-standardised grass allergy immunotherapy tablet in European and North American children and adolescents. Allergy 2011;66(Suppl. 94):164-319
25. Dehlink E, Eiwegger T, Gerstmayr M, et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006;36:32-9
26. Rolinck-Werninghaus C, Kopp M, Liebke C, et al. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005;136:134-41
27. Malling HJ, Lund L, Ipsen H, et al. Safety and immunological changes during sublingual immunotherapy with standardized quality grass allergen tablets. J Investig Allergol Clin Immunol 2006;16:162-8
28. Aberer W, Hawranek T, Reider N, et al. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy. J Investig Allergol Clin Immunol 2007;17:131-6
29. Panizo C, Cimarra M, Gonzalez-Mancebo E, et al. In vivo and in vitro immu-nological changes induced by a short course of grass allergy immunotherapy tablets. J Investig Allergol Clin Immunol 2010;20:454-62
30. Durham SR, Riis B. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage. Allergy 2007;62:954-7
31. Durham SR, Birk AO, Andersen JS. Days with severe symptoms: an additional efficacy endpoint in immunotherapy trials. Allergy 2011;66:120-3
32. Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64(Suppl 91):1-59
33. Juniper EF, Stahl E, Doty RL, et al. Clinical outcomes and adverse effect monitoring in allergic rhinitis. J Allergy Clin Immunol 2005;115(3 Suppl 1):S390-413
34. Davies RR, Smith LP. Forecasting the start and severity of the hay fever season. Clin Allergy 1973;3:263-7
35. Emberlin J, Jaeger S, Dominguez-Vilches E, et al. Temporal and geographical variations in grass pollen seasons in areas of western Europe: an analysis of season dates at sites of European pollen information system. Aerobiologia 2000;16:373-9
36. D'Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe. Allergy 2007;62:976-90
37. Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131-8
38. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717-25
39. Lombardi C, Gargioni S, Venturi S, et al. Controlled study of preseasonal immunotherapy with grass pollen extract in tablets: effect on bronchial hyper-reactivity. J Investig Allergol Clin Immunol 2001;11:41-5
40. Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969-75
41. Ott H, Sieber J, Brehler R, et al. Efficacy of grass pollen sublingual immuno-therapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:1394-401
42. Valovirta E, Herland Berstad A, de Blic J, et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjuctivitis. Clin Ther 2011;33:1537-1546
43. Nassar S, VestenbÌk U, Beriot-Mathiot A, et al. Cost-effectiveness of specific immunotherapy with Grazax in allergic rhinitis co-existing with asthma. Allergy 2008;63:1624-1629